MA-16N7C2

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameMA-16N7C2
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsThrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAfrica +[4
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDendreon San Diego Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDendreon San Diego Llc
Active IndicationsN/A
Inactive IndicationsThrombosis

Other Information

ATC CodeN/A
Related LinksN/A